John Duncan Higgons, Director at Jounce Therapeutics, Inc. (JNCE), sold 200 shares at $11.78 ($2K) on 2021-02-16, disclosed to the SEC on 2021-02-18.
Scheduled sale ($2k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| JNCE | SELL | 2021-01-22 | $20K | — | Filing → |
| JNCE | SELL | 2020-01-08 | $12K | — | Filing → |
| JNCE | BUY | 2017-02-02 | $107K | — | Filing → |